The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
NCT ID: NCT05540327
Last Updated: 2026-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
379 participants
INTERVENTIONAL
2022-09-16
2028-08-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
NCT05162586
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481
Study of M5049 in CLE and SLE Participants
NCT04647708
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
NCT01205438
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04961567
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
M5049 high dose + Placebo
Participants with CLE (active SCLE and/or DLE) or SLE who received M5049 matched placebo or high dose of M5049 in WILLOW study will receive M5049 high dose .
M5049 high dose
Participants will receive film-coated tablets of M5049 at a high dose orally, BID for up to 194 weeks.
Placebo
Participants will receive M5049 matching placebo orally, BID for up to 194 weeks.
M5049 low dose + Placebo
Participants with CLE (active SCLE and/or DLE) or SLE who received low dose of M5049 in WILLOW study will continue to receive M5049 low dose and matching placebo.
M5049 low dose
Participants will receive film-coated tablets of M5049 at a low dose orally, twice a day (BID) for up to 194 weeks.
Placebo
Participants will receive M5049 matching placebo orally, BID for up to 194 weeks.
M5049 medium dose+ Placebo
Participants with CLE (active SCLE and/or DLE) or SLE who received medium dose of M5049 in WILLOW study will continue to receive M5049 medium dose and matching placebo.
M5049 medium dose
Participants will receive film-coated tablets of M5049 at a medium dose orally, BID for up to 194 weeks.
Placebo
Participants will receive M5049 matching placebo orally, BID for up to 194 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
M5049 low dose
Participants will receive film-coated tablets of M5049 at a low dose orally, twice a day (BID) for up to 194 weeks.
M5049 medium dose
Participants will receive film-coated tablets of M5049 at a medium dose orally, BID for up to 194 weeks.
M5049 high dose
Participants will receive film-coated tablets of M5049 at a high dose orally, BID for up to 194 weeks.
Placebo
Participants will receive M5049 matching placebo orally, BID for up to 194 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have a Body Mass Index (BMI) within the less than or equal to (\<=) 40 kilograms per meter square (inclusive) at Screening
* Participants who had successfully completed Week 48 of the Part 1 will have the opportunity to participate in the LTE Part 2. In exceptional cases and after Sponsor review, participants who have completed the Week 48 visit of the Part 1 within the previous 4-weeks may be considered for Part 2 participation based on eligibility review. Previous 4-weeks will be calculated from the Week 48 visit of Part 1
Exclusion Criteria
* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with Long Term Extension (LTE) study participation
* Ongoing or active clinically significant viral (including Severe acute respiratory syndrome coronavirus 2 \[(SARS-CoV-2)\], bacterial or fungal infection, or any major episode of infection requiring hospitalization
* Received LTE prohibited medication during the WILLOW study or after the WILLOW study Week 24
* Participation in any other investigational drug study after the WILLOW study Week 24
18 Years
76 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Responsible
Role: STUDY_DIRECTOR
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Lundquist Institute at Harbor-UCLA Medical Center
Torrance, California, United States
Bay Area Arthritis and Osteoporosis
Brandon, Florida, United States
Advance Medical Research Center
Miami, Florida, United States
Dawes Fretzin Dermatology Group, LLC
Indianapolis, Indiana, United States
AA MRC LLC Ahmed Arif Medical Research Center
Grand Blanc, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Ohio State University - CTMO Parent
Columbus, Ohio, United States
Ramesh C Gupta, MD
Memphis, Tennessee, United States
Centro de Investigaciones Medicas Mar del Plata - CIM
Buenos Aires, , Argentina
CINME - Centro De Investigaciones Metabolicas
Buenos Aires, , Argentina
Buenos Aires Skin
Ciudad Autonoma Buenos Aires, , Argentina
Hospital Militar Central Dr. Cosme Argerich
Ciudad Autonoma Buenos Aires, , Argentina
Centro de Investigaciones Medicas Mar del Plata - CIM
Mar del Plata, , Argentina
Instituto de Reumatologia
Mendoza, , Argentina
Instituto Medico de alta Complejidad San Isidro S.A (IMAC)
San Fernando, , Argentina
CER San Juan Centro Polivalente de Asistencia e Inv. Clinica
San Juan, , Argentina
Centro Dermatologico Schejtman
San Miguel, , Argentina
PSORIAHUE-Medicina Interdisciplinar
San Miguel, , Argentina
Centro de Investigaciones Medicas Tucuman
San Miguel de Tucumán, , Argentina
Investigaciones Clinicas Tucuman
San Miguel de Tucumán, , Argentina
Monash Medical Centre Clayton
Clayton, , Australia
Veracity Clinical Research
Woolloongabba, , Australia
Santa Casa de Misericórdia de Belo Horizonte
Belo Horizonte, , Brazil
Oncovida - Centro de Onco-Hematologia de Mato Grosso
Cuiabá, , Brazil
Clínica SER da Bahia
Graça, , Brazil
CMiP - Centro Mineiro de Pesquisa
Juiz de Fora, , Brazil
Hospital Moinhos de Vento
Moinhos de Vento, , Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto - CIP - Centro Integrado de Pesquisa
São José, , Brazil
CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos
São Paulo, , Brazil
DCC 'Sveti Georgi' EOOD - Cardiology Office
Haskovo, , Bulgaria
MC Artmed OOD
Plovdiv, , Bulgaria
DCC 1 Sevlievo EOOD
Sevlievo, , Bulgaria
DCC Focus 5 - MEOH OOD
Sofia, , Bulgaria
Military Medical Academy - MHAT - Sofia
Sofia, , Bulgaria
UMHAT "Sv. Ivan Rilski", EAD - Clinic of Rheumatology
Sofia, , Bulgaria
UMHAT "Sv. Ivan Rilski", EAD - Clinica of Rheumatology
Sofia, , Bulgaria
Clinica Alemana de Osorno - Corporacion de Beneficencia Osorno
Los Lagos, , Chile
BioMedica Research Group - Psicomedica Clinical and Research Group
Santiago, , Chile
CeCim Biocinetic
Santiago, , Chile
Centro Medico Prosalud
Santiago, , Chile
CIEC- Centro Internacional de Estudios Clinicos - Valenzuela Y Compania Ltda
Santiago, , Chile
Dermacross
Santiago, , Chile
The First Affiliated Hospital of Baotou Medical College
Baotou, , China
Peking Union Medical College Hospital - Beijing Union Medical College Hospital
Beijing, , China
The First Hospital of Jilin University
Changchun, , China
Guangdong Provincial People's Hospital
Guangzhou, , China
Hainan General Hospital
Haikou, , China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, , China
The Second Affiliated Hospital of Nanchang University
Nanchang, , China
The Affiliated Drum Tower Hospital of Nanjing University
Nanjing, , China
Huashan Hospital, Fudan University - Neurology
Shanghai, , China
Renji Hospital Shanghai Jiaotong University School of Medicine - West Branch
Shanghai, , China
Shanghai Skin Disease Hospital
Shanghai, , China
West China Hospital, Sichuan University
Sichuan, , China
The First Affiliated Hospital of Soochow University
Suzhou, , China
Tianjin Medical University General Hospital
Tianjin, , China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, , China
Centro de Investigacion Medico Asistencial S.A.S
Barranquilla, , Colombia
Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM
Bogotá, , Colombia
Servimed S.A.S.
Bucaramanga, , Colombia
Centro Integral de Reumatologia del Caribe SAS CIRCARIBE SAS
Medellín, , Colombia
Healthy Medical Center
Zipaquirá, , Colombia
General Hospital of Athens Laiko
Athens, , Greece
General Hospital Papageorgiou
Thessaloniki, , Greece
Chaim Sheba Medical Center - pt
Ramat Gan, , Israel
NHO Asahikawa Medical Center - Dept of Gastroenterology
Asahikawa-shi, , Japan
NHO Chibahigashi National Hospital - Dept of Allergy/Rheumatology
Chiba, , Japan
St. Luke's International Hospital - Dept of Immunology/Allergy
Chūōku, , Japan
Hiroshima University Hospital
Hiroshima, , Japan
Eiraku Clinic - Dept of Rheumatology
Kagoshima, , Japan
Saitama Medical Center - Dept of Rheumatology/Immunology
Kawagoe-shi, , Japan
Kagawa University Hospital - Dept of Immunology/ Rheumatology
Kita-gun, , Japan
Hokkaido University Hospital - Dept of Internal Medicine 2(Rheumatology/Immunolog
Sapporo, , Japan
Tohoku University Hospital - Dept of Hematology/Immunology
Sendai, , Japan
CAP Research Ltd
Quatre Bornes, , Mauritius
Consultorio Privado Dr. Miguel Cortes Hernandez
Cuernavaca, , Mexico
Centro de Estudios de Investigacion Basica y Clinica SC
Guadalajara, , Mexico
Diseno y Planeacion en Investigacion Medica S.C.
Guadalajara, , Mexico
Diseño y Planeacion en Investigacion Medica S.C.
Guadalajara, , Mexico
Centro Medico del Angel
Mexicali, , Mexico
CAIMED Investigacion en salud S.A de C.V.
Mexico City, , Mexico
Clinstile, S.A. de C.V.
Mexico City, , Mexico
Medical Care & Research SA de CV
Mérida, , Mexico
Centro de Investigacion Clínica GRAMEL S.C
México, , Mexico
Clinica para el Diagnostico y Tratamiento de las Enfermedades Reumaticas
México, , Mexico
Consultorio de Reumatologia - Hospital Angeles Lindavista Cons. 445B
México, , Mexico
Grupo Medico Camino S.C.
México, , Mexico
Centro Regiomontano de Estudios Clínicos Roma S.C.
Monterrey, , Mexico
CIMAB S.A. de C.V. - Centro de Investigacion Medica Alberto Bazzoni
Torreón, , Mexico
ICS ARENSIA Exploratory Medicine SRL - Republican Clinical Hospital "Timofei Mosneaga"
Chisinau, , Moldova
Davao Doctors Hospital - Medicine
Davao City, , Philippines
Iloilo Doctors Hospital
Iloilo City, , Philippines
Mary Mediatrix Medical Center
Lipa City, , Philippines
Ospital Ng Makati
Makati City, , Philippines
Chinese General Hospital & Medical Center
Manila, , Philippines
Far Eastern University - Dr. Nicanor Reyes Medical Foundation - Department of Child Health
Quezon City, , Philippines
Nova Reuma Domysławska i Rusiłowicz, Spółka Partnerska Lekarza Reumatologa i Fizjoterapeuty
Bialystok, , Poland
Prywatna Praktyka Lekarska prof Pawel Hrycaj
Kościan, , Poland
Centrum Medyczne Plejady
Krakow, , Poland
Centrum Nowoczesnych Terapii Dobry Lekarz
Krakow, , Poland
Twoja Przychodnia PCM
Poznan, , Poland
Twoja Przychodnia-Szczecinskie Centrum Medyczne Sp. z o. o
Szczecin, , Poland
Clinical Best Solutions - Warszawa
Warsaw, , Poland
Centrul Medical Monza SRL - Arensia Exploratory Medicine
Bucharest, , Romania
S.C Delta Health Care S.R.L - Ponderas Academic Hospital
Bucharest, , Romania
Spitalul Clinic "Sf. Maria" - Clinica de Medicina Interna si Reumatologie
Bucharest, , Romania
Spitalul Clinic "Sf. Maria" - parent
Bucharest, , Romania
Institute of Rheumatology - Rheumatology
Belgrade, , Serbia
Institute of Rheumatology
Belgrade, , Serbia
University Clinical Center of Serbia - Clinic of Alergology and Imunology
Belgrade, , Serbia
Arthritis Clinical Research Trial Unit - Dr CE Spargo and Dr RB Bhorat
Cape Town, , South Africa
University of Pretoria Clinical Research Unit - Parent
Pretoria, , South Africa
Naidoo, A - Netcare Umhlanga Hospital
Umhlanga, , South Africa
Gachon University Gil Medical Center
Incheon, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Ajou University Hospital
Suwon, , South Korea
Hospital General de Castellon - Servicio de Reumatologia
Castelló, , Spain
Hospital Regional Universitario de Malaga - Reumatology Dept
Málaga, , Spain
Hospital Universitario Marques de Valdecilla - Servicio de Reumatologia
Santander, , Spain
Hospital Universitario Rio Hortega - Servicio de Medicina Interna
Valladolid, , Spain
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Trial Awareness and Transparency website
Medical Information Location Map - Med Info Contacts
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-000239-21
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
MS200569_0048
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.